NuCana plc – NASDAQ:NCNA
Founder-led company
NuCana stock price today
$3.7
+2.28
+160.56%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
NuCana stock price monthly change
-54.92%
month
NuCana stock price quarterly change
-54.92%
quarter
NuCana stock price yearly change
+373.33%
year
NuCana key metrics
Market Cap | 4.94M |
Enterprise value | N/A |
P/E | -1.41 |
EV/Sales | N/A |
EV/EBITDA | 0.04 |
Price/Sales | N/A |
Price/Book | 0.67 |
PEG ratio | -0.38 |
EPS | -12.58 |
Revenue | N/A |
EBITDA | -29.59M |
Income | -26.60M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNuCana stock price history
NuCana stock forecast
NuCana financial statements
| Jun 2023 | 0 | -5.41M | |
|---|---|---|---|
| Sep 2023 | 0 | -6.69M | |
| Dec 2023 | 0 | -7.65M | |
| Mar 2024 | 0 | -6.83M |
| Sep 2025 | 0 | -63.19K | |
|---|---|---|---|
| Dec 2025 | 0 | -53.60K | |
| Dec 2025 | 0 | -62.55K | |
| Mar 2026 | 0 | -61.98K |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 41257000 | 13.87M | 33.63% |
|---|---|---|---|
| Sep 2023 | 33967000 | 12.19M | 35.9% |
| Dec 2023 | 27811000 | 12.92M | 46.47% |
| Mar 2024 | 24801000 | 14.67M | 59.16% |
| Jun 2023 | -5.85M | 23K | -33K |
|---|---|---|---|
| Sep 2023 | -10.17M | 2.64M | 64K |
| Dec 2023 | -77K | 53K | -43K |
| Mar 2024 | -5.88M | 43K | 1.38M |
NuCana alternative data
| Aug 2023 | 28 |
|---|---|
| Sep 2023 | 28 |
| Oct 2023 | 28 |
| Nov 2023 | 28 |
| Dec 2023 | 28 |
| Jan 2024 | 28 |
| Feb 2024 | 28 |
| Mar 2024 | 28 |
| Apr 2024 | 28 |
| May 2024 | 25 |
| Jun 2024 | 25 |
| Jul 2024 | 25 |
NuCana other data
33.56%
-7.05%
of NCNA is owned by hedge funds
17.46M
-3.71M
shares is hold by hedge funds
| Patent |
|---|
Grant Utility: Floxuridine synthesis Filling date: 18 Sep 2018 Issue date: 16 Aug 2022 |
Grant Utility: Synthesis of phosphate derivatives Filling date: 14 Jun 2018 Issue date: 16 Aug 2022 |
Grant Utility: Cancer treatments Filling date: 31 May 2017 Issue date: 2 Aug 2022 |
Grant Utility: Crystalline form of gemcitabine Filling date: 21 Dec 2016 Issue date: 5 Jul 2022 |
Grant Utility: 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds Filling date: 5 Feb 2020 Issue date: 7 Jun 2022 |
Application Filling date: 19 May 2021 Issue date: 3 Feb 2022 |
Application Filling date: 18 May 2021 Issue date: 3 Feb 2022 |
Application Filling date: 15 Apr 2021 Issue date: 3 Feb 2022 |
Application Filling date: 1 Oct 2021 Issue date: 27 Jan 2022 |
Application Filling date: 6 Apr 2021 Issue date: 27 Jan 2022 |
| Insider | Compensation |
|---|---|
Mr. Hugh Stephen Griffith (1968) Founder, Chief Executive Officer & Executive Director | $1,240,000 |
Prof. Christopher B. Wood FRCS, M.D., Ph.D. (1946) Chief Medical Officer | $111,880 |
NuCana: Pipeline And Major Gilead Litigation Progressing Nicely
NuCana: An Intriguing 'Sum Of The Parts' Story
NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead
NuCana: Preparing For A Critical 2022
NuCana: The Market Continues To Overlook Its ProTide Platform Technology
NuCana: Starting A Speculative Position At An Astonishing Risk-Reward
-
What's the price of NuCana stock today?
One share of NuCana stock can currently be purchased for approximately $3.7.
-
When is NuCana's next earnings date?
Unfortunately, NuCana's (NCNA) next earnings date is currently unknown.
-
Does NuCana pay dividends?
No, NuCana does not pay dividends.
-
How much money does NuCana make?
NuCana has a market capitalization of 4.94M.
-
What is NuCana's stock symbol?
NuCana plc is traded on the NASDAQ under the ticker symbol "NCNA".
-
What is NuCana's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of NuCana?
Shares of NuCana can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NuCana's key executives?
NuCana's management team includes the following people:
- Mr. Hugh Stephen Griffith Founder, Chief Executive Officer & Executive Director(age: 57, pay: $1,240,000)
- Prof. Christopher B. Wood FRCS, M.D., Ph.D. Chief Medical Officer(age: 79, pay: $111,880)
-
Is NuCana founder-led company?
Yes, NuCana is a company led by its founder Mr. Hugh Stephen Griffith.
-
How many employees does NuCana have?
As Jul 2024, NuCana employs 25 workers, which is 11% less then previous quarter.
-
When NuCana went public?
NuCana plc is publicly traded company for more then 7 years since IPO on 28 Sep 2017.
-
What is NuCana's official website?
The official website for NuCana is nucana.com.
-
How can i contact NuCana?
NuCana can be reached via phone at +44 131 357 1111.
NuCana company profile:
NuCana plc
nucana.comExchange:
NASDAQ
Full time employees:
25
Industry:
Biotechnology
Sector:
Healthcare
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
3 Lochside Way
Edinburgh, EH12 9DT
Edinburgh, EH12 9DT
CIK: 0001709626
ISIN: US67022C1062
CUSIP: 67022C106
